Reply

We thank Kelso1 for his comments on our case-control study,2 and his questions regarding the proportion of reactions that occurred outside of the observation period recommended by the Omalizumab-Associated Anaphylaxis Joint Task Force.3

http://ift.tt/2mEB7xA